SGLT2 inhibitors reduced the risk of major adverse cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) in individuals both receiving and not receiving GLP-1RA (HR 0.81
Clinical evidence demonstrates that GLP-1 medications continue to provide metabolic benefits, including improved glycaemic control and, in people with type 2 diabetes, cardiovascular risk reduction, even when weight loss stabilises
Even when netted out for rebates and payment assistance, a year of treatment can approach five figures
This occurs because of the reduced production of red blood cells, which can cause your skin to appear pale
Discontinuation of GLP-1 therapy may result in weight regain and recurrence of hepatic steatosis, emphasizing the need for long-term treatment strategies
Combined with pricing hidden behind the intake and misleading ad pricing, theres a pattern of selective honesty